Silence Therapeutics (LON:SLN) has extended its R&D collaboration with AstraZeneca (LON:AZN) by one year. The companies are jointly collaborating to identify and optimise five novel siRNA therapeutic molecules, which address respiratory and oncology indications.
The R&D collaboration is independent of the companies separate siRNA delivery collaboration, which was extended in April 2010.
Small interfering RNA (siRNA), also known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules that most notably, is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene.
"The extension of our development collaboration with AstraZeneca is testament to the successful relationship and the progress made in this collaboration”, Silence chief executive Philip Haworth said. “AstraZeneca is a strong endorsement of our technology and we are delighted to continue working together."
Under the terms of the agreement, which has progressed well since being signed in July 2007, Silence and AstraZeneca are jointly collaborating to identify and optimise five novel siRNA therapeutic molecules, which address respiratory and oncology indications.
Silence said that its team interacts closely with AstraZeneca's operational units - including Medimmune in the US and its teams in Sweden, the UK and China - to progress the development of the siRNA molecules identified as a result of the collaboration.
"AstraZeneca remains committed to the development of new therapeutic technologies that have the potential to create novel therapies. We are very pleased with the progress we have made in our collaborative agreement with Silence Therapeutics,", AstraZeneca VP of Respiratory and Inflammation Research, Thomas Eichholtz commented.
Under the terms of the collaboration agreement, AstraZeneca retains full responsibility for the clinical development and commercialization of the siRNA molecules. Silence highlighted that the R&D collaboration may generate up to £200m in fees and milestone payments plus royalties on product sales, in addition to the £7.5 million access fee paid to Silence in July 2007.
According to Silence, it has “one of the most comprehensive and sophisticated RNAi therapeutic platforms,” which is comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company believes that these three areas are critical to building, protecting and commercializing RNAi therapeutics.